Cyclacel Pharmaceuticals Inc CYCC

Alternate Symbol(s): CYCCP

Healthcare Biotechnology

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.

NDAQ:CYCC - Post by User

Cyclacel Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Mar 26, 2024 1:58pm

47 Views

Post# 35953508

CYCC....what I'm finding out with these "thinners" is

Mr. M is maniping this to the max....what u see is not what you get.

Level II is all smoke and mirrors....total BS

Just try buying or selling creatively....you will see how the maddapakkas work their book

What a f'king game

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China